California-based biopharmaceutical company Alumis is making significant strides towards the launch of its novel oral psoriasis treatment, envudeucitinib. Following the release of compelling Phase III data from its ONWARD program, the company is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026. While envudeucitinib demonstrates promising efficacy and a favorable safety profile, it is set to enter an increasingly competitive landscape, facing established players and innovative new entrants in the oral psoriasis market.
The ONWARD program, comprising three distinct Phase III studies (ONWARD 1, ONWARD 2, and ONWARD 3), was designed to rigorously evaluate the efficacy and safety of envudeucitinib in patients with moderate to severe plaque psoriasis. The results, which have been met with optimism by Alumis, underscore the drug’s potential to offer a durable and meaningful impact on disease severity, itching, and overall quality of life for patients. However, the path to market success will require Alumis to effectively differentiate envudeucitinib against a formidable roster of existing and emerging therapies.
The ONWARD Program: A Deep Dive into Efficacy and Durability
Alumis’s confidence in envudeucitinib is largely built upon the robust data generated from the ONWARD clinical trials. The core of the program involved two randomized, controlled studies, ONWARD 1 and ONWARD 2, which directly compared envudeucitinib against both placebo and Amgen’s established oral psoriasis medication, Otezla (apremilast). Complementing these were the findings from the open-label ONWARD 3 study, which focused on the long-term efficacy and safety of envudeucitinib, allowing patients from the initial trials to continue treatment and providing invaluable insights into the sustained benefits of the drug.
Key Efficacy Endpoints and Sustained Benefits:
The ONWARD studies have highlighted several critical areas where envudeucitinib has shown significant promise:
-
Disease Severity (PASI Score): Building upon earlier indications, the Phase III data revealed that a substantial 54% of patients treated with twice-daily envudeucitinib achieved a complete response, as measured by the Psoriasis Area and Severity Index (PASI) scale, at the 48-week mark. This signifies a complete or near-complete clearing of psoriasis lesions across their body. This sustained reduction in disease severity is a crucial indicator of a drug’s long-term effectiveness.
-
Scalp Psoriasis Clearance: Scalp psoriasis is a particularly challenging and visible manifestation of the disease that significantly impacts a patient’s quality of life. The ONWARD 3 study demonstrated that an impressive 80% of patients maintained a scalp considered clear or almost clear of psoriasis at 48 weeks of treatment. This sustained control of scalp involvement is a notable achievement and a potential differentiator for the drug.
-
Itch Reduction: The debilitating itch associated with psoriasis is often one of the most distressing symptoms for patients. The ONWARD 1 and 2 studies indicated that approximately one in three patients treated with envudeucitinib experienced a clinically meaningful reduction in itch within just two weeks of commencing treatment. Furthermore, this relief proved to be durable, with 80% of patients in the ONWARD 3 study maintaining this significant itch reduction up to 48 weeks. The rapid onset and sustained impact on itching are particularly important for improving a patient’s daily comfort and well-being.
-
Quality of Life (QoL) Improvements: Beyond the visible signs of psoriasis and the physical discomfort, the disease profoundly affects a patient’s daily life. Envudeucitinib has shown a positive impact on this crucial aspect. At week 12, half of the treated patients reported that their psoriasis had minimal to no impact on their daily quality of life. This positive trajectory continued, with over 70% of patients maintaining this level of improved QoL after 48 weeks of treatment in the ONWARD 3 study.
Safety and Tolerability: A Cornerstone for Long-Term Use
A critical factor for any new medication, especially for chronic conditions like psoriasis, is its safety profile and tolerability. Alumis has reported that patients generally tolerated envudeucitinib well throughout the ONWARD program. Crucially, researchers identified no new safety signals associated with long-term treatment, suggesting a favorable risk-benefit profile for patients who require sustained management of their condition. This absence of novel safety concerns is a significant positive development and will be a key factor in regulatory review and physician adoption.
The Competitive Landscape: A Crowded Arena
Alumis’s ambition to secure approval for envudeucitinib in plaque psoriasis is set against a backdrop of an increasingly dynamic and competitive market. The oral psoriasis treatment space has seen significant innovation in recent years, and envudeucitinib will need to carve out its niche among established and emerging therapies.
Key Competitors and Their Strengths:
-
Bristol Myers Squibb’s Sotyktu (deucravacitinib): As a fellow tyrosine kinase 2 (TYK2) inhibitor, Sotyktu represents a direct competitor to envudeucitinib. Sotyktu has already established a market presence, generating $291 million in sales last year. Alumis aims to leverage envudeucitinib’s potentially enhanced mechanism of action, with the drug engineered to engage and inhibit TYK2 over a full 24-hour period, suggesting a potentially more consistent therapeutic effect.
-
Johnson & Johnson’s Icotyde (icotrokinra): This newly approved psoriasis pill has generated considerable buzz. Analysts have lauded Icotyde for achieving "biologic-like efficacy in a once-daily oral pill," a significant advantage in terms of patient convenience. This contrasts with envudeucitinib’s twice-daily dosing requirement, a factor that could influence patient preference and adherence. The market anticipation for Icotyde suggests it could become a blockbuster seller, posing a significant challenge.
-
Amgen’s Otezla (apremilast): While Otezla was used as a comparator in the ONWARD studies, it remains a significant player in the oral psoriasis market. Its established track record and physician familiarity make it a benchmark against which new therapies are measured.
-
Takeda’s Zasocitinib: This investigational psoriasis drug from Takeda is also a TYK2 inhibitor and is being closely watched by the industry. While specific efficacy comparisons are still emerging, its development highlights the intense research and development efforts focused on this pathway.
Challenges to Differentiation:
The competitive pressures are significant. Jefferies analysts have raised concerns that the dosing schedule of envudeucitinib, coupled with data that may position its efficacy below that of both Icotyde and Takeda’s zasocitinib, could potentially limit its ability to differentiate itself in the eyes of clinicians and patients. Successfully navigating this challenge will require Alumis to clearly articulate the unique benefits of envudeucitinib, potentially focusing on specific patient populations or highlighting its long-term safety profile and durability.
The Road Ahead: Regulatory Submission and Market Entry
With the positive Phase III data in hand, Alumis is now focused on the critical step of submitting its New Drug Application (NDA) to the FDA. This submission, anticipated in Q4 2026, will initiate the regulatory review process, during which the FDA will scrutinize the comprehensive data package to determine the drug’s safety and efficacy for the treatment of plaque psoriasis.
If approved, envudeucitinib will aim to capitalize on the unmet needs within the psoriasis market. While existing treatments offer varying degrees of relief, there remains a significant demand for oral therapies that provide rapid, sustained, and well-tolerated symptom control with minimal impact on a patient’s daily life. Alumis’s strategy will likely involve emphasizing the unique aspects of envudeucitinib’s mechanism of action, its demonstrated durability, and its favorable safety profile in the context of long-term management.
The journey from clinical trial success to market leadership is complex. Alumis will need to engage in robust post-marketing surveillance, ongoing research to further understand envudeucitinib’s role in different patient subgroups, and strategic marketing efforts to effectively communicate its value proposition to healthcare providers and patients. The company’s ability to articulate a compelling narrative that addresses the concerns of a discerning market, particularly in light of the emerging competition, will be paramount to envudeucitinib’s success in the crowded oral psoriasis landscape.
About the Author
